JP2020518276A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518276A5 JP2020518276A5 JP2019561141A JP2019561141A JP2020518276A5 JP 2020518276 A5 JP2020518276 A5 JP 2020518276A5 JP 2019561141 A JP2019561141 A JP 2019561141A JP 2019561141 A JP2019561141 A JP 2019561141A JP 2020518276 A5 JP2020518276 A5 JP 2020518276A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- human
- nuclease
- nucleic acid
- engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101700080605 NUC1 Proteins 0.000 claims 10
- 210000004027 cells Anatomy 0.000 claims 10
- 101700006494 nucA Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 4
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 2
- 108091008153 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 1
- 241000432074 Adeno-associated virus Species 0.000 claims 1
- 229920000033 CRISPR Polymers 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 108020004999 Messenger RNA Proteins 0.000 claims 1
- 230000002759 chromosomal Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002452 interceptive Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920002106 messenger RNA Polymers 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Claims (6)
- 遺伝子改変ヒトT細胞を産生する方法であって、前記方法は、
(a)核酸分子を前記ヒトT細胞に導入すること、ここで、前記核酸分子は、
(i)キメラ抗原受容体をコードする核酸配列を含む第1の発現カセットと;
(ii)ベータ2ミクログロブリンに対して阻害性であるRNA干渉分子をコードする核酸配列を含む第2の発現カセットと;
(iii)5’相同性アームと;
(iv)3’相同性アームと;を含み、前記5’相同性アーム及び前記3’相同性アームが、T細胞受容体(TCR)アルファ定常領域遺伝子内のヌクレアーゼ認識配列に隣接する染色体領域と相同性を有し、
及び
(b)前記ヌクレアーゼ認識配列に対して特異性を有する操作されたヌクレアーゼをコードするmRNAを前記ヒトT細胞に導入すること、ここで、前記操作されたヌクレアーゼが前記細胞内で発現され;
を含み、
ここで、前記核酸分子が、AAV6の血清型を有するアデノ随伴ウイルス(AAV)ベクターを使用して前記ヒトT細胞に導入され、
前記操作されたヌクレアーゼが、前記ヒトT細胞のゲノム中の前記ヌクレアーゼ認識配列に結合して切断し、切断部位を生成し、
前記核酸分子が、相同組換えにより前記切断部位で前記ヒトT細胞のゲノムに挿入され、及び
前記遺伝子改変ヒトT細胞でのベータ2ミクログロブリンの細胞表面発現が、細胞表面ベータ2ミクログロブリン発現を低下させるように遺伝子改変されていない対照細胞での細胞表面ベータ2ミクログロブリン発現と比較して、約90%から約95%低下している、遺伝子改変ヒトT細胞を産生する方法。 - 前記操作されたヌクレアーゼが、操作されたメガヌクレアーゼ、TALEN、ジンクフィンガーヌクレアーゼ(ZFN)、CRISPR/Cas、コンパクトTALEN、又はメガTALである、請求項1記載の方法。
- 前記操作されたヌクレアーゼが、操作されたメガヌクレアーゼである、請求項1又は2に記載の方法。
- 前記ヌクレアーゼ認識配列が配列番号1からなる、請求項1〜3のいずれか一項に記載の方法。
- 請求項1〜4のいずれか一項に記載の方法により作製された、遺伝子改変ヒトT細胞。
- 薬学的に許容可能な担体と、治療的有効量の請求項5に記載の前記遺伝子改変ヒトT細胞と、を含む、医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022175346A JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762503060P | 2017-05-08 | 2017-05-08 | |
US62/503,060 | 2017-05-08 | ||
US201762579460P | 2017-10-31 | 2017-10-31 | |
US62/579,460 | 2017-10-31 | ||
PCT/US2018/031674 WO2018208837A1 (en) | 2017-05-08 | 2018-05-08 | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022175346A Division JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020518276A JP2020518276A (ja) | 2020-06-25 |
JP2020518276A5 true JP2020518276A5 (ja) | 2021-06-10 |
JP7170666B2 JP7170666B2 (ja) | 2022-11-14 |
Family
ID=62555183
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019561141A Active JP7170666B2 (ja) | 2017-05-08 | 2018-05-08 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
JP2022175346A Pending JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022175346A Pending JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Country Status (6)
Country | Link |
---|---|
US (3) | US10745665B2 (ja) |
EP (2) | EP3634493A1 (ja) |
JP (2) | JP7170666B2 (ja) |
AU (1) | AU2018266698A1 (ja) |
CA (1) | CA3062698A1 (ja) |
WO (1) | WO2018208837A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111954679A (zh) | 2017-10-03 | 2020-11-17 | 朱诺治疗学股份有限公司 | Hpv特异性结合分子 |
JP2021520202A (ja) * | 2018-04-05 | 2021-08-19 | ジュノー セラピューティクス インコーポレイテッド | 組換え受容体を発現する細胞の作製方法および関連組成物 |
CN113748126A (zh) * | 2018-11-30 | 2021-12-03 | 因提玛生物科学公司 | 鉴定免疫调节基因的方法 |
KR20210148293A (ko) | 2019-04-03 | 2021-12-07 | 프리시젼 바이오사이언시스 인코포레이티드 | 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포 |
US20220313737A1 (en) * | 2019-06-18 | 2022-10-06 | Celyad Oncology S.A. | Cd52-deficient cells for adoptive cell therapy |
EP4034641A4 (en) * | 2019-09-26 | 2024-01-03 | Nantbio Inc | PRIMARY MULTIPLICATION OF T CELLS |
CN116134144A (zh) * | 2020-04-23 | 2023-05-16 | Az治疗股份有限公司 | 细胞的hla-i类mhc消融 |
WO2022093863A1 (en) * | 2020-10-26 | 2022-05-05 | Research Institute At Nationwide Children's Hospital | Chimeric antigen receptor (car) nk cells and uses thereof |
CR20230303A (es) | 2020-12-11 | 2023-09-01 | Intellia Therapeutics Inc | Composiciones y métodos para reducir el mhc de clase ii en una célula |
AU2021409732A1 (en) | 2020-12-23 | 2023-07-20 | Intellia Therapeutics, Inc. | Compositions and methods for reducing hla-a in a cell |
BR112023012432A2 (pt) | 2020-12-23 | 2023-11-07 | Intellia Therapeutics Inc | Composições e métodos para modificação genética de ciita em uma célula |
TW202235615A (zh) | 2020-12-30 | 2022-09-16 | 美商英特利亞醫療公司 | 工程化之t細胞 |
WO2022165111A1 (en) | 2021-01-28 | 2022-08-04 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
CN117042794A (zh) | 2021-02-08 | 2023-11-10 | 因特利亚治疗公司 | 用于免疫疗法的t细胞免疫球蛋白和粘蛋白结构域3(tim3)组合物和方法 |
CN117098840A (zh) | 2021-02-08 | 2023-11-21 | 因特利亚治疗公司 | 用于免疫疗法的自然杀伤细胞受体2b4组合物和方法 |
EP4288088A2 (en) | 2021-02-08 | 2023-12-13 | Intellia Therapeutics, Inc. | Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy |
CN117940153A (zh) | 2021-08-24 | 2024-04-26 | 因特利亚治疗公司 | 用于基于细胞的疗法的程序性细胞死亡蛋白1(pd1)组合物和方法 |
WO2023081200A2 (en) | 2021-11-03 | 2023-05-11 | Intellia Therapeutics, Inc. | Cd38 compositions and methods for immunotherapy |
WO2023245108A2 (en) | 2022-06-16 | 2023-12-21 | Intellia Therapeutics, Inc. | Compositions and methods for reducing mhc class i in a cell |
WO2024006955A1 (en) | 2022-06-29 | 2024-01-04 | Intellia Therapeutics, Inc. | Engineered t cells |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
ATE310812T1 (de) | 1994-01-18 | 2005-12-15 | Scripps Research Inst | Derivate von zinkfingerproteinen und methoden |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
JP4118327B2 (ja) | 1994-08-20 | 2008-07-16 | ゲンダック・リミテッド | Dna認識のための結合タンパク質におけるまたはそれに関連する改良 |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
ATE347593T1 (de) | 2002-01-23 | 2006-12-15 | Univ Utah Res Found | Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen |
EP2368982A3 (en) | 2002-03-21 | 2011-10-12 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
WO2004037977A2 (en) | 2002-09-05 | 2004-05-06 | California Institute Of Thechnology | Use of chimeric nucleases to stimulate gene targeting |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
SG10201508995QA (en) | 2005-07-26 | 2015-11-27 | Sangamo Biosciences Inc | Targeted integration and expression of exogenous nucleic acid sequences |
US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
DK1945762T3 (da) | 2005-10-18 | 2013-07-29 | Prec Biosciences | Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet |
EP2215223B1 (en) | 2007-10-31 | 2013-05-01 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
ES2527997T5 (es) | 2009-12-10 | 2018-05-17 | Regents Of The University Of Minnesota | Modificación del ADN inducida por el efector TAL |
CA2832534C (en) | 2011-04-05 | 2022-01-04 | Julien Valton | Method for the generation of compact tale-nucleases and uses thereof |
GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
EP3116902B1 (en) | 2014-03-11 | 2020-01-01 | Cellectis | Method for generating t-cells compatible for allogenic transplantation |
CA2964948A1 (en) | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
US20180161368A1 (en) | 2015-05-29 | 2018-06-14 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
MX2018004146A (es) | 2015-10-05 | 2018-11-09 | Prec Biosciences Inc | Células modificadas genéticamente que comprenden un gen mano modificado de la región constante alfa del receptor de células t. |
ES2901000T3 (es) * | 2015-12-23 | 2022-03-21 | Prec Biosciences Inc | Meganucleasas de ingeniería con secuencias de reconocimiento encontradas en el gen de la microglobulina beta-2 humana |
KR20220047898A (ko) * | 2016-03-11 | 2022-04-19 | 2세븐티 바이오, 인코포레이티드 | 게놈 편집 면역 효과기 세포 |
-
2018
- 2018-05-08 CA CA3062698A patent/CA3062698A1/en active Pending
- 2018-05-08 EP EP18729846.8A patent/EP3634493A1/en not_active Withdrawn
- 2018-05-08 JP JP2019561141A patent/JP7170666B2/ja active Active
- 2018-05-08 AU AU2018266698A patent/AU2018266698A1/en active Pending
- 2018-05-08 WO PCT/US2018/031674 patent/WO2018208837A1/en unknown
- 2018-05-08 EP EP21209275.3A patent/EP4029943A1/en active Pending
-
2019
- 2019-11-08 US US16/678,600 patent/US10745665B2/en active Active
-
2020
- 2020-07-13 US US16/927,452 patent/US20200339952A1/en not_active Abandoned
-
2022
- 2022-04-04 US US17/712,864 patent/US20220228115A1/en active Pending
- 2022-11-01 JP JP2022175346A patent/JP2023022005A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020518276A5 (ja) | ||
CN114085836B (zh) | 用于减少pd-l1表达的寡核苷酸 | |
Nelson et al. | Engineering delivery vehicles for genome editing | |
AU2016335572B2 (en) | Compositions and methods for treating Huntington's disease and related disorders | |
JP2019522461A5 (ja) | ||
JP2018534950A5 (ja) | ||
JP2016538885A5 (ja) | ||
JP2023165986A (ja) | ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子 | |
CN112930395A (zh) | 靶向rna的融合蛋白组合物和使用方法 | |
JP2019528769A5 (ja) | ||
JP2021518102A (ja) | 異常ヘモグロビン症の治療のためのシステム及び方法 | |
JP2018512162A5 (ja) | ||
JP2019524140A5 (ja) | ||
RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
JP2010273685A5 (ja) | ||
RU2013152648A (ru) | Аденовирус обезьян и гибридные аденовирусные векторы | |
JP2016500262A5 (ja) | ||
US11939575B2 (en) | Modified tracrRNAs gRNAs, and uses thereof | |
JP2017524348A5 (ja) | ||
JP2020517270A5 (ja) | ||
JP2015524413A5 (ja) | ||
JP2016513457A5 (ja) | ||
WO2019147743A1 (en) | Structure-guided chemical modification of guide rna and its applications | |
JP2013518599A5 (ja) | ||
WO2020092904A1 (en) | Recombinant parvoviral vectors and method of making and use thereof |